Drug Repurposing Against Sars Cov 2

Drug repurposing is a cost-effective method of discovering new treatments for diseases than traditional drug development methods. It involves virtual screening of chemical candidates with the aid of computational methods like molecular docking. Drug Repurposing against SARS-CoV2 focuses on current trends in drug repurposing against the novel coronavirus strains. The book aims to give readers an overview of drug repurposing against COVID-19 and various techniques involved in the process. The book consolidates available information on the pathophysiology, drug targets, and drug repurposing against COVID-19 into a single, convenient resource. Key features • An up-to-date compilation of the evidence that supports the drug repurposing for COVID-19. • How to use repurposing of available drugs for disease therapy. • Provides an improved understanding of pathophysiology and SARS-CoV2 viral entry pathways. • Provides references for further reading

Drug repurposing is a cost-effective method of discovering new treatments for diseases than traditional drug development methods. It involves virtual screening of chemical candidates with the aid of computational methods like molecular docking. Drug Repurposing against SARS-CoV2 focuses on current trends in drug repurposing against the novel coronavirus strains. The book aims to give readers an overview of drug repurposing against COVID-19 and various techniques involved in the process. The book consolidates available information on the pathophysiology, drug targets, and drug repurposing against COVID-19 into a single, convenient resource. Key features - An up-to-date compilation of the evidence that supports the drug repurposing for COVID-19. - How to use repurposing of available drugs for disease therapy. - Provides an improved understanding of pathophysiology and SARS-CoV2 viral entry pathways. - Provides references for further reading

Drug repurposing is a cost-effective method of discovering new treatments for diseases than traditional drug development methods. It involves virtual screening of chemical candidates with the aid of computational methods like molecular docking. Drug Repurposing against SARS-CoV2 focuses on current trends in drug repurposing against the novel coronavirus strains. The book aims to give readers an overview of drug repurposing against COVID-19 and various techniques involved in the process. The book consolidates available information on the pathophysiology, drug targets, and drug repurposing against COVID-19 into a single, convenient resource. Key features * An up-to-date compilation of the evidence that supports the drug repurposing for COVID-19. * How to use repurposing of available drugs for disease therapy. * Provides an improved understanding of pathophysiology and SARS-CoV2 viral entry pathways. * Provides references for further reading

Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV2 Infection: Revolutionary Strategies to Combat Pandemics compiles information about various computational bioinformatic approaches that can help combat viral infection. The book includes working knowledge of various molecular docking and molecular dynamic simulation approaches that have been exploited for drug repurposing and drug designing purpose. In addition, it sheds light on reverse vaccinomics and immunoinformatic approaches for vaccine designing against SARS-CoV2 infection. This book is an essential resource for researchers, bioinformaticians, computational biologists, computational chemists and pharmaceutical companies who are working on the development of effective and specific therapeutic interventions and point-of-care diagnostic devices using various computational approaches. Covers computational based approaches for designing and repurposing drugs Discusses immunoinformatic and reverse vaccinomic approaches for effective vaccine design Categorizes information about artificial intelligence-based drug screening and diagnostic tools

Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health. In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful. Discusses the pathogenic mechanisms of SARS-CoV-2 and druggable targets Reviews the various signaling pathways associated with SAR-CoV-2 as possible druggable targets Presents computational approaches and in silico studies against SARS-CoV-2

This book highlights the different aspects of the research project “E4C Horizon 2020 European Project” aimed at fighting the coronavirus by combining the best supercomputing resources and artificial intelligence with state-of-the-art experimental facilities up through clinical validation. Coronavirus disease has become an important public issue across the globe since December 2019. There is an urgent need to develop potent anti-COVID-19 agents for the prevention of the outbreak and stop viral infections. To this aim, a public–private consortium composed by European and national infrastructures, center of excellence, universities, and a pharmaceutical company started the E4C Horizon 2020 European Project: Its core idea was to use the EXaSCale smArt pLatform Against paThogEns (EXSCALATE) supercomputing platform for a process known as “drug repurposing”, namely to identify the most promising safe in man drugs for immediate treatment of the already infected population and then novel pan-coronavirus inhibitors to address future emergencies. This ambitious goal exploited a “chemical library” of 500 billion molecules, thanks to a processing capacity of more than 3 million molecules per second, made available by the computing power of the EXSCALATE platform.

COVID-19 has spread like wildfire across the globe since the start of the SARS-CoV-2 outbreak, hampering quality of life at multiple levels and causing many deaths. Many aspects of the human experience have been affected, with a body of research being published on its effects on psychological and physical well being, loss of jobs, pay cuts, education, and unpaid caregiving. New findings on these aspects are still emerging as we learn more about the consequences of the pandemic. This book is intended as a simple summary of recent findings about COVID-19 for academicians and students from science, humanities and commerce backgrounds to understand the pandemic from a microscopic view and how it has touched our lives at different levels. A collection of topics is presented and explored through chapters dedicated to niche topics on COVID-19. Each chapter is authored by expert scientists, academicians and scholars from leading institutions in India. The key features of this book set are: - Interdisciplinary content, making it useful for readers from different academic streams - A blend of basic and applied research in biology, medicine and social science - A focus on findings from India - Updated References for advanced readers This collection of topics is invaluable for researchers and working professionals in industry and academia as well as general readers who want a broad, insightful perspective on COVID-19.